Skip to main content

Advertisement

Table 2 Symptom free days by country and ARIA severity

From: Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey

  Total FF MF FP
  N Mean (SD) N Mean (SD) N β 95% CI N β 95% CI
Symptom-free days 417 14.58 (8.42) 208 15.45 (8.29) 102 −1.22 −3.16 to 0.72 107 −1.95 −3.87 to −0.03
Country sub-groups           
  France 152 14.45 (8.74) 75 16.15 (8.43) 36 −3.03 −6.37 to 0.32 41 −2.77 −6.03 to 0.49
  Germany 165 16.19 (7.70) 83 16.45 (7.74) 42 −0.81 −3.68 to 2.07 40 −0.59 −3.50 to 2.33
  Spain 100 12.12 (8.51) 50 12.74 (8.51) 24 1.48 −2.56 to 5.53 26 −0.98 −4.99 to 3.03
Severity sub-groups           
  Mild intermittent 50 18.72 (8.34) 26 20.23 (7.69) 9 −1.77 −9.12 to 5.58 15 −2.30 −8.68 to 4.08
  Moderate/severe intermittent 138 15.21 (7.57) 74 15.05 (7.49) 38 1.44 −1.57 to 4.46 26 −1.76 −5.23 to 1.70
  Moderate/severe persistent 229 13.30 (8.62) 108 14.56 (8.62) 55 −2.50 −5.29 to 0.28 66 −1.95 −4.58 to 0.69
  1. FF: Fluticasone furoate; FP: Fluticasone propionate; MF: Mometasone furoate; β = adjusted mean difference from FF.